View Exam | PowerPak

1. Which of the following is TRUE regarding the medical uses of botulinum toxin?

A. Doses and dosing intervals for a particular indication should be followed to provide the optimum opportunity for successful therapy B. Using this medication more often than prescribed will improve health outcomes without risk of serious adverse effects C. Obtaining botulinum toxin injections from more than 1 medical professional at a time will not increase the risk of adverse effects D. The effects of a botulinum toxin injection are permanent and repeat injections are unnecessary E. Unsure

2. Which of the following statements is TRUE regarding the interchangeability of botulinum toxin products?

A. Only botulinum toxins of the same subtype (e.g., subtype A1) are interchangeable B. Given differences in products and activity assays, the botulinum toxin products are not considered to be interchangeable C. Established dose equivalencies can be used to interchange between botulinum toxin products within a course of therapy D. Botulinum toxin products are interchangeable only with prior authorization E. Unsure

3. Which of the currently available botulinum toxin products is NOT available as a sterile powder for reconstitution?

A. OnabotulinumtoxinA (Botox®) B. RimabotulinumtoxinB (Myobloc®) C. IncobotulinumtoxinA (Xeomin®) D. AbobotulinumtoxinA (Dysport®) E. Unsure

4. The professional practice committee of the Academy of Managed Care Pharmacy (AMCP) published a set of principles to guide the development of effective prior authorization practices. Which of the following is NOT one of the principles included in the guidelines?

A. Transparency and advanced notice B. Provider collaboration C. Emergency access D. Shared cost considerations E. Unsure

5. TN is a 44-year-old woman with overactive bladder. She has received numerous medications to treat her symptoms with limited to no success. Which of the following would be an appropriate course of therapy?

A. OnabotulinumtoxinA administered with a 6–12-week dosing interval B. OnabotulinumtoxinA administered with a 12–24-week dosing interval C. IncobotulinumtoxinA administered with a 6–12-week dosing interval D. IncobotulinumtoxinA administered with a 12–24-week dosing interval E. Unsure

6. A pharmacist handles prior authorization for specialty drugs while working with a physician's office under a collaborative practice agreement. One of the patients is a 57-year-old male with lower limb spasticity. The physician prescribes abobotulinumtoxinA 1500 units every 12 weeks. Which of the following actions would be considered appropriate for prior authorization and dispensing?

A. Dispense the product before receiving prior authorization B. Use manufacturer's marketing materials to justify the use of abobotulinumtoxinA C. Request prior authorization for 84 days in the treatment cycle, not 90 days D. Change the dosing interval to 90 days E. Unsure

7. Botulinum toxins are approved for the treatment of a variety of medical conditions. Which of the following is NOT a United States Food and Drug Administration-approved indication for onabotulinumtoxinA (Botox®)?

A. Chronic sialorrhea B. Pediatric lower and upper limb spasticity (ages 2–17 years) C. Chronic migraine D. Neurogenic detrusor overactivity E. Unsure

8. Naturally occurring botulinum toxins are typically expressed with accessory or chaperone proteins. Which of the following botulinum toxin agents is formulated without such accessory proteins?

A. OnabotulinumtoxinA (Botox®) B. AbobotulinumtoxinA (Dysport®) C. IncobotulinumtoxinA (Xeomin®) D. RimabotulinumtoxinB (Myobloc®) E. Unsure

9. While botulinum toxin products have a very low rate of adverse events, there is a risk of iatrogenic botulism with botulinum toxin therapy potentially caused by overdosage and/or spread of botulinum toxin from the site of injection. Which of the following is a sign or symptom of botulism?

A. Nausea and vomiting B. Excessive sweating C. Constipation D. Breathing difficulties E. Unsure

10. When treating someone for primary axillary hyperhidrosis with onabotulinumtoxin A, which of the following patient counseling points should you advise the patient of?

A. Antiperspirant or deodorant should be avoided for 24 hours before and after treatment B. The underarm area should be shaved approximately 8 hours before treatment C. Caffeinated products should be avoided for 24 hours before and after treatment D. Caffeinated products should be avoided for 8 hours before and after treatment E. Unsure

Evaluation Questions

11. How confident are in your treatment choice for TN in question 5?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is TRUE regarding the medical uses of botulinum toxin?

2. Which of the following statements is TRUE regarding the interchangeability of botulinum toxin products?

3. Which of the currently available botulinum toxin products is NOT available as a sterile powder for reconstitution?

4. The professional practice committee of the Academy of Managed Care Pharmacy (AMCP) published a set of principles to guide the development of effective prior authorization practices. Which of the following is NOT one of the principles included in the guidelines?

5. TN is a 44-year-old woman with overactive bladder. She has received numerous medications to treat her symptoms with limited to no success. Which of the following would be an appropriate course of therapy?

7. Botulinum toxins are approved for the treatment of a variety of medical conditions. Which of the following is NOT a United States Food and Drug Administration-approved indication for onabotulinumtoxinA (Botox®)?

8. Naturally occurring botulinum toxins are typically expressed with accessory or chaperone proteins. Which of the following botulinum toxin agents is formulated without such accessory proteins?

9. While botulinum toxin products have a very low rate of adverse events, there is a risk of iatrogenic botulism with botulinum toxin therapy potentially caused by overdosage and/or spread of botulinum toxin from the site of injection. Which of the following is a sign or symptom of botulism?

10. When treating someone for primary axillary hyperhidrosis with onabotulinumtoxin A, which of the following patient counseling points should you advise the patient of?

Evaluation Questions

11. How confident are in your treatment choice for TN in question 5?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following is TRUE regarding the medical uses of botulinum toxin?

2. Which of the following statements is TRUE regarding the interchangeability of botulinum toxin products?

3. Which of the currently available botulinum toxin products is NOT available as a sterile powder for reconstitution?

4. The professional practice committee of the Academy of Managed Care Pharmacy (AMCP) published a set of principles to guide the development of effective prior authorization practices. Which of the following is NOT one of the principles included in the guidelines?

5. TN is a 44-year-old woman with overactive bladder. She has received numerous medications to treat her symptoms with limited to no success. Which of the following would be an appropriate course of therapy?

7. Botulinum toxins are approved for the treatment of a variety of medical conditions. Which of the following is NOT a United States Food and Drug Administration-approved indication for onabotulinumtoxinA (Botox®)?

8. Naturally occurring botulinum toxins are typically expressed with accessory or chaperone proteins. Which of the following botulinum toxin agents is formulated without such accessory proteins?

9. While botulinum toxin products have a very low rate of adverse events, there is a risk of iatrogenic botulism with botulinum toxin therapy potentially caused by overdosage and/or spread of botulinum toxin from the site of injection. Which of the following is a sign or symptom of botulism?

10. When treating someone for primary axillary hyperhidrosis with onabotulinumtoxin A, which of the following patient counseling points should you advise the patient of?

Evaluation Questions

11. How confident are in your treatment choice for TN in question 5?

« Return to Activity

Customers who Purchased
this Activity also Purchased